Dr. Anne T. Bruinvels (Founder and Chief Scientific Officer)

Anne has more than 17 years of experience in the pharmaceutical and biotechnology industry. Prior to founding Curidium, Anne was Scientific Director, Business Development at Pharmagene (now Asterand), where she contributed to the growth of the organisation from private start-up to publicly listed biotechnology company. Previously, she has led research groups, as Head of Neurogenetics, SmithKline Beecham Pharmaceuticals (now GlaxoSmithkline) and as Head of Neuroanatomy and co-leader of global schizophrenia research at Wyeth. Anne was awarded a PhD scholarship at Sandoz Pharma (now Novartis) and obtained her PhD (neuroscience) from Utrecht University (the Netherlands). She was presented with the London Biotechnology Network "Young Entrepreneur of the Year Award" in 2003.

Dr. Ann Hayes (Non-Executive Director)

Ann worked for 22 years for Glaxo and then GlaxoWellcome, initially in research, with particular expertise in the areas of CNS and pain. Before the GlaxoSmithkline merger, she was a director in drug discovery, and was involved in determining long-term discovery strategy, in portfolio management and in discovery project management. Ann left GlaxoSmithkline in 2001 and set up a business as an independent pharmaceutical consultant. In this capacity she has co-founded two small pharmaceutical businesses, Ionix Pharmaceuticals which has since been bought by Vernalis, and TheraSci, which was sold to CeNeS. In addition to her directorship at Curidium, Ann is a director for Plethora Solutions plc and Theradeas Ltd., and a member of the advisory boards for Paradigm Therapeutics, BrainCells Inc. and CeNeS plc.

Mr. Simon Cartmell (Non-Executive Chairman)

Simon has 24 years pharmaceutical, healthcare and biotechnology industry experience. He spent 17 years at GlaxoWellcome (now GlaxoSmithkline) in a number of UK and global roles, including therapy area director, infectious diseases and hepatitis and supply chain director, responsible for the global order and fulfilment process from GlaxoSmithkline’s seven UK manufacturing sites. Simon joined Vernalis plc (formerly Vanguard Medica plc) as chief operating officer in 1998 overseeing its acquisition of the neurosciences company Cerebrus plc in 1999. Following this he joined the main board of Celltech in the role of chief executive officer, of Celltech Pharmaceuticals, a major player in the US ADHD market. Upon leaving Celltech in mid 2002, Simon has worked with the venture capital and biotech community in a variety of interim CEO, business development and consulting roles. In addition to his role as chairman of Curidium, he is currently CEO of ApaTech Ltd, a spine focused medical technology company and chairman of OSspray Ltd, a dental materials company.

Dr. Barry Porter (Chairman)

Barry is a Director of Union Life Sciences and an Non-Executive Director of Inhibox Limited. Barry has almost thirty years of drug discovery experience working in the pharmaceutical industry. He was Chief Executive of ReOx Ltd, a biotechnology spin out from the University of Oxford which entered into a ground breaking co-development deal with a major international biopharmaceutical company in its first year of operations. Prior to these roles, Barry held senior positions at De Novo Pharmaceuticals, Pharmagene, now Asterand, Rhone-Poulenc Rorer and Glaxo Group Research. He gained his PhD from the University of California, San Diego followed by a post doctoralfellowship with Syntex in Palo Alto.

Dr. Gosse B. Bruinsma (Non-Executive Director)

Gosse has over 20 years of experience in the medical, pharmaceutical and biotechnology fields. He received his undergraduate degree from McGill University, Montreal and his medical degree from the University of Leiden, the Netherlands. Following several years in clinical medicine, he joined the pharmaceutical industry to become European Medical Director for Zambon, Milan. He subsequently joined the international contract research organization, ClinTrials Research, to become their Vice President for Medical and Regulatory Affairs. In 1995 Gosse joined Forest Laboratories in New York as Medical Director. From 1997 to 1999 he was General Manager and VP Development for Chrysalis Clinical Services Europe based in Switzerland. From 1999 until he joined Axonyx Europe BV, Dr. Bruinsma was the VP Development for Crucell BV (formerly IntroGene), a biotechnology company based in the Netherlands. Gosse served as Chairman and Chief Executive Officer of OXIS International in 2004. Gosse served as a Director of Axonyx Inc. and as President of Axonyx Europe BV since 2000, as Chief Operating Officer of Axonyx Inc. since 2001, as President of Axonyx Inc. since 2003 and as Chief Executive Officer until he successfully merged the company with a private USA-based company in 2006. Gosse currently serves as Director on the Supervisory Board of Agendia BV based in Amsterdam and advises several other companies at executive and Board level.

Dr. Smita Price (Director of Psychiatry Research)

Smita Price (formerly Smita Patel) joined Curidium Ltd. in April 2006, with over 15 years experience in CNS drug discovery and development at Merck, Neuroscience Research Centre, UK. At Merck, Smita successfully managed multiple CNS projects, led the Target Evaluation team within Exploratory Psychiatry and contributed to the advancement of in-licensing opportunities, CNS portfolio management and drug development strategies. Prior to joining Merck, Smita conducted research on epilepsy as a Postdoctoral Fellow with Professor Brian Meldrum at the Institute of Psychiatry in London. Smita received her PhD in Physiology from the University of Manchester and a BSc (Hons) in Pharmacology from the University of Cardiff, S. Wales.

Dr. Phyllis E. Whiteley (Non-Executive Director)

Phyllis is an Entrepreneur-In-Residence with 5AM Ventures.  She also serves as a director of the US Personalized Medicine Coalition.  Previously, Phyllis was an Officer and Senior Vice President of Business Development and Licensing of Perlegen Inc., a US based personalized medicine company. Prior to Perlegen, Phyllis was Vice President Strategic Portfolio Management, Global Pharma Research Strategy for F. Hoffman La Roche. During her ten year tenure with Roche she held various positions including Vice President Business Development and Global Licensing Director based in Basel, Switzerland and other research leadership positions including Therapeutic Area Head. Prior to Roche, Phyllis was with Merck. She holds a Ph.D., Pharmacology from Washington University, St. Louis, Missouri.

Mr. Robert Smith (Finance Director)

Rob joined Curidium in January 2007. Previously Rob was Chief Executive of Densitron Technologies plc having assumed this position in October 2005 before that he was Finance Director having joined that Group in 2002. Rob led Densitron through a number of changes including the sale of subsidiary companies, fund raising and negotiation of sales and distribution agreements. Rob is a Chartered Management Accountant, has an MSc in Management Accounting and over 20 years of experience in the Electronics Industry.